Edesa Biotech (EDSA) Total Non-Current Liabilities (2019 - 2023)

Edesa Biotech has reported Total Non-Current Liabilities for 5 years, with the latest figure at $1.6 million in Q2 2023.

• Quarterly Total Non-Current Liabilities fell 72.27% year-over-year to $1.6 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $1.6 million (down 72.27% YoY) and the FY2022 annual result came in at $2.1 million, up 44.73% from the prior year.
• Total Non-Current Liabilities retreated to $1.6 million in Q2 2023 per EDSA's latest filing, from $1.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $5.7 million in Q2 2022 and troughed at $461634.0 in Q3 2019.
• A 5-year average of $2.1 million and a median of $1.6 million in 2020 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities soared 451.83% in 2022, then tumbled 72.27% in 2023.
• Over 5 years, Total Non-Current Liabilities stood at $461634.0 in 2019, then soared by 113.64% to $986250.0 in 2020, then surged by 77.12% to $1.7 million in 2021, then decreased by 22.32% to $1.4 million in 2022, then advanced by 15.62% to $1.6 million in 2023.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $1.6 million, $1.6 million, and $1.4 million for Q2 2023, Q1 2023, and Q4 2022 respectively.